Compare Gilead Sciences, Inc. (GILD) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Microchip Technology Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while Microchip Technology Inc. trades at $81.9 (market cap $46.84B). The key difference: Gilead Sciences, Inc. is far larger — about 3.5× Microchip Technology Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MCHP | |
|---|---|---|
Market Cap | $163.51B | $46.84B |
Sector | Health | Technology |
52-Week High | $155.80 | $102.97 |
52-Week Low | $108.22 | $49.02 |
Enterprise Value | $178.05B | $52.13B |
Dividend Yield | 2.49% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Microchip Technology (MCHP) trades at $82.18, down 5.66% today, with a bearish technical signal but strong analyst consensus. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.57 surpassing the $0.505 estimate. The company maintains a solid gross margin of 57.73% but reported a net loss in 2025. Positive news highlights growth in AI, industrial IoT, and aerospace sectors, with new product launches like the VectorBlox 3.0 SDK and space-grade clock generators.
MCHP shows potential from AI and aerospace demand, with a $113.33 average price target implying 38% upside. However, high valuations (P/E 392.09, P/S 9.98) and recent net income challenges pose risks. Investors should weigh robust cash flow and market positioning against debt levels and cyclical semiconductor pressures. The stock's outlook hinges on execution in recovering end-markets and sustaining earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
